 |
|
 |
South Africa |
|
|
The Medical Device Market: South Africa
Publication Date December 2007
Publisher Espicom
Product Type Report
Pages 126
ISBN Number not applicable
Product Code ESP417
|
|
|
Summary
Espicom''s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
|
Content
- Executive Summary
- Inflammatory Bowel Disease
- What Is Inflammatory Bowel Disease?
- Risk Factors in The Development of Ibd
- Where in The World?
- The Ibd Therapy Market
- Ibd Management
- Current Treatment Options
- Aminosalicylates
- Sulphasalazine
- Oral Mesalamine
- Topical Mesalamine
- Olsalazine
- Balsalazide
- Corticosteroids
- Prednisone
- Budesonide
- Hydrocortisone
- Immunosuppressants
- 6-mercaptopurine
- Azathioprine
- Cyclosporine
- Methotrexate
- Tumour Necrosis Factor Alpha Inhibitors
- What's in The Pipeline?
- Potential New Drugs for Ibd
- Competitor Ratio Analysis
- Tumour Necrosis Factor Alpha Inhibitors
- Remicade (infliximab)
- Sales forecast
- Clinical trial results
- Paediatric Crohn's Disease
- Ulcerative Colitis
- Humira (adalimumab)
- Sales forecast
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Cimzia (certolizumab pegol)
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- PRECiSE clinical trial programme
- RDP58 (delmitide)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Golimumab
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Cell Adhesion Molecule Inhibitors
- Tysabri (natalizumab)
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Alicaforsen
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Firategrast (SB683699)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- MLN0002
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Novel Corticosteroids
- COLAL-PRED (prednisolone)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertiseERIES
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- T-cell modulators
- Nuvion (visilizumab)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Orencia (abatacept)
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Immune System Modulators
- Alequel
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Interleukin Inhibitors
- ABT-874
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- STA-5326
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Map Kinase Inhibitors
- Semapimod
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Others
- Traficet-EN
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- AST-120
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- HMPL-004
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Promising Early-Stage Development Candidates
- Irritable Bowel Syndrome
- What Is Irritable Bowel Syndrome?
- Where in The World?
- The Ibs Therapy Market
- Ibs Management
- Current Treatment Options
- Antispasmodics
- Laxatives
- Antidiarrhoeal Agents
- Antidepressants
- Serotonergic Agents
- What's in The Pipeline?
- Potential New Drugs for Ibs
- Competitor Ratio Analysis
- Serotonergic Agents
- Lotronex (alosetron)
- Zelnorm (tegaserod)
- Sales forecast
- Clinical trial results
- IBS with mixed bowel pattern
- DDP225
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- DDP733
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Renzapride
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Others
- Amitiza (lubiprostone)
- Sales forecast and assumptions
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Linaclotide acetate
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Dexloxiglumide
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Dextofisopam
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Xifaxan (rifaximin)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Crofelemer
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Gastro-Oesophageal Reflux Disease
- What Is Gastro-Oesophageal Reflux Disease?
- The Gord Therapy Market
- GORD management
- H2 receptor antagonists
- Pepcid/Gaster (famotidine)
- Zantac (ranitidine)
- Axid (nizatidine)
- Tagamet (cimetidine)
- Proton pump inhibitors
- AcipHex/Pariet (rabeprazole)
- Nexium (esomeprazole)
- Prevacid (lansoprazole)
- Losec/Prilosec (omeprazole)
- Protonix (pantoprazole)
- What's in The Pipeline?
- Competitor Ratio Analysis
- Potential New Drugs for Gord
- ATI-7505
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- DDP733
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- OX 17
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- ADX10059
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- XP19986
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical trial results
- Sources
- Others
- List of Tables
- Genes associated with IBD
- IBD patient forecasts 2005-2012
- Currently available aminosalicylates
- Currently available corticosteroids
- Immunosuppressants currently used in IBD
- Drugs in developmentfor IBD
- Competitor ratio analysis summary
- Remicade sales, 2002-2006 (US$ millions)
- Humira sales, 2003-2006 (US$ millions)
- Currently available antidepressants
- Drugs in development for IBS
- Competitor ratio analysis summary
- Competitor Ratio Score: 42
- Sales of leading drugs used in GORD management (US$ millions)
- Approved H2 receptor antagonists
- Gaster Sales, 2003-2007 ( & US$ million)
- Zantac sales, 2002-2006 ( & US$ million)
- Approved proton pump inhibitors
- AcipHex/Pariet sales, 2002-2006 ( & US$ million)
- Nexium sales, 2002-2006 (US$ million)
- Prevacid/Takepron sales, 2002-2006 ( & US$ million)
- Losec/Prilosec sales, 2002-2006 (US$ million)
- Protonix/Pantozol sales, 2002-2006 (EUR & US$ million)
- Drugs in development for GORD
- Competitor ratio analysis summary
- List of Figures
- IBD prevalence 2007
- Drugs in clinical development for IBD by activity
- Remicade projected sales, 2006-2012 (US$ million)
- Humira projected sales 2006-2012 (US$ millions)
- Cimzia projected sales 2008-2012 (US$ millions)
- Golimumab projected sales, 2010-2014 (US$ million)
- ABT-874 projected sales, 2009-2014 (US$ millions)
- Amitiza, projected sales 2006-2012 (US$ millions)
- Gaster projected sales, 2007-2012 (US$ Million)
- Zantac projected sales, 2006-2012 (US$ million)
- AcipHex/Pariet projected sales, 2007-2012 (US$ million)
- Nexium projected sales, 2006-2012 (US$ million)
- Prevacid/Takepron projected sales, 2006-2012 (US$ million)
- Losec/Prilosec projected sales, 2006-2012 (US$ million)
- Protonix/Pantozol projected sales, 2006-2012 (US$ million)
|
|
|
